Shots:
The EMA’s CHMP has adopted a positive opinion recommending marketing authorization of Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets as monotherapy for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received ≥1 prior systemic therapy; if approved by the EC, it would be the first broad RAS-targeted treatment option in the EU for these…
